

YR0501

Leader in Biomolecular Solutions for Life Science



# Human CD19 Monoclonal Antibody

Catalog No.: YR0501

## Basic Information

### Molecular Weight

150 kDa

### Endotoxin

<1EU/mg (<0.001EU/μg) Determined by LAL gel clotting assay

### Sterility

0.2 μm filtration

### Aggregation

<5% Determined by SECP

### Purity

>95% Determined by SDS-PAGE

## Background

Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab shows antitumor activity and has potential application in non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL).

## Reported Applications

ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways

## Immunogen Information

### Clone

Loncastuximab Biosimilar

### Isotype

Human IgG1 kappa

### Immunogen

### Recommended Isotype Control(s)

### Recommended Dilution Buffer

1×PBS pH 7.3

## Contact



[www.abclonal.com](http://www.abclonal.com)

## Product Information

### Production

Purified from cell culture supernatant in an animal-free facility


### Purification

Protein A or G purification


### Storage

Store at 2 - 8°C. 2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)

# Validation Data



Direct ELISA binding curve demonstrating the recognition of Human Anti-Human CD19 (Research Grade Loncastuximab Biosimilar) Monoclonal Antibody to CD19. The target protein was coated onto the microplate well surface, followed by binding of the antibody. A donkey anti-human IgG HRP conjugate was used for detection.



Human CD19 SPR assay. Determined through SPR assay, the Human Anti-Human CD19 (Research Grade Loncastuximab Biosimilar) Monoclonal Antibody is Capable of binding to Human CD19 with an affinity constant of 1.193n M.